drugset / Trial / NCT01315496
GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.
Timeline
- Start
- 2009-10
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immunoglobulin G | Protein / enzyme biologic | 1.5 g/kg | Intravenous |
| Subject | Immunoglobulin G | Protein / enzyme biologic | 2 g/kg | Intravenous |